Results for: Payers

Here we present our overview of the original subscription-based payment model proposed and the proposals put forth by Louisiana and Washington.

The Drug Pricing Lab takes issue with The New York Times ‘Fact Check’ on the recent Trump Administration proposal to pilot alternative reimbursement for Part B drugs.

Our analysis provides an estimate of the revenues or gross profits associated with prescription drugs’ path from the manufacturer to the patient.

In a JAMA Viewpoint, DPL’s Anna Kaltenboeck and Dr. Peter Bach offer a taxonomy of the features that make a payment model truly value-based.

Anna Kaltenboeck and Dr. Peter Bach published commentary in Morning Consult, describing key misconceptions surrounding outcomes-based contracting, and what steps are needed to make the approach value-based.

The DPL uses a real world example of a patient's utilization of Mylan's copay coupon for Epipens to demonstrate the effects of such programs.

In this paper, we discuss the unique features of the market for anticancer drugs and assess trends in the launch prices for 58 anticancer drugs approved between 1995 and 2013 in the United States.

Dr. Peter Bach responds to industry leaders who argue that high prices are necessary for innovation.

Dr. Peter Bach discusses how copay assistance programs are actually causing drug prices to rise on Closing Bell.

Dr. Bach argues drug company copay and coupon programs actually play a significant role in keeping prescription drug costs in the U.S. high

A new analysis reviews payment questions posed by Members of Congress regarding CMS’ proposed Part B drug payment demonstration program.

New analysis in BMJ looks at avoidable excess medicine and waste in top 20 U.S. cancer drugs and how to prevent it